- Home
- HAVA vs IMUX Comparison
HAVA vs IMUX Comparison
Compare HAVA & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HAVA | IMUX |
|---|---|---|
| Founded | 2024 | 2016 |
| Country | South Korea | United States |
| Employees | N/A | 66 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.0M | 209.2M |
| IPO Year | 2025 | 2013 |
Fundamental Metrics
Financial Performance| Metric | HAVA | IMUX |
|---|---|---|
| Price | $10.19 | $16.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 44.5K | ★ 143.9K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $0.51 |
| 52 Week High | $10.19 | $17.43 |
Technical Indicators
Market Signals| Indicator | HAVA | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 64.29 | 62.63 |
| Support Level | $9.98 | $0.75 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.01 | 1.08 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 100.00 | 80.21 |
Price Performance
Historical ComparisonAbout HAVA Harvard Ave Acquisition Corporation Class A Ordinary Share
Harvard Ave Acquisition Corp is a blank check company.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.